| abstract |
The present invention provides a new class of androgen receptor target substances (ARTA) that are selective androgen receptor modulators (SARMs). Some of the SARM compounds have been found to have unexpected androgenic activity and anabolic activity as non-steroidal ligands for the androgen receptor. Another SARM compound has been found to have unexpected antiandrogenic activity as a non-steroidal ligand for the androgen receptor. These SARM compounds are: (a) male contraception, (b) treatment of various hormone-related illnesses (DAM-related illnesses in older men), (c) treatment of illnesses related to ADIF, (d) acute And / or treatment and / or prevention of chronic muscle atrophy, (e) treatment and / or prevention of dry eye, (f) oral androgen replacement therapy, (g) reduction of the onset of prostate cancer, or (h) prostate It is effective for stopping or regression of cancer. |